BIOGEN INC. Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax of $28.60 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-06.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax · last filed 2020-02-06
- BIOGEN INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments, after tax for fiscal 2019 was $28.60M, a 472.00% increase from fiscal 2018.
- BIOGEN INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments, after tax for fiscal 2018 was $5.00M.
- BIOGEN INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments, after tax for fiscal 2017 was $0.00.
- BIOGEN INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments, after tax for fiscal 2016 was $0.00.
| Period end | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax 12 month |
|---|---|
| 2019-12-31 | $28.60M 10-K · filed 2020-02-06 |
| 2018-12-31 | $5.00M 10-K · filed 2020-02-06 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-06 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |